Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 14
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Moises, H W Wollschläger, D and Binder, H 2015. Functional genomics indicate that schizophrenia may be an adult vascular-ischemic disorder. Translational Psychiatry, Vol. 5, Issue. 8, p. e616.


    van Buel, E M Patas, K Peters, M Bosker, F J Eisel, U L M and Klein, H C 2015. Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all?. Translational Psychiatry, Vol. 5, Issue. 7, p. e609.


    Wesseling, H. Gottschalk, M. G. and Bahn, S. 2015. Targeted Multiplexed Selected Reaction Monitoring Analysis Evaluates Protein Expression Changes of Molecular Risk Factors for Major Psychiatric Disorders. International Journal of Neuropsychopharmacology, Vol. 18, Issue. 1, p. pyu015.


    Bates, R.C. Stith, B.J. Stevens, K.E. and Adams, C.E. 2014. Reduced Chrna7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABAA receptor subunits. Neuroscience, Vol. 273, p. 52.


    Mickley, G. Andrew Hoxha, Zana DiSorbo, Anthony Wilson, Gina N. Remus, Jennifer L. Biesan, Orion Ketchesin, Kyle D. Ramos, Linnet Luchsinger, Joseph R. Prodan, Suzanna Rogers, Morgan Wiles, Nathanael R. and Hoxha, Nita 2014. Latent inhibition of a conditioned taste aversion in fetal rats. Developmental Psychobiology, Vol. 56, Issue. 3, p. 435.


    Ruan, Linhui Lau, Benson Wui-Man Wang, Jixian Huang, Lijie ZhuGe, Qichuan Wang, Brian Jin, Kunlin and So, Kwok-Fai 2014. Neurogenesis in neurological and psychiatric diseases and brain injury: From bench to bedside. Progress in Neurobiology, Vol. 115, p. 116.


    Winchester, Catherine L. Pratt, Judith A. and Morris, Brian J. 2014. Risk genes for schizophrenia: Translational opportunities for drug discovery. Pharmacology & Therapeutics, Vol. 143, Issue. 1, p. 34.


    Ewing, Samuel G. and Winter, Christine 2013. The ventral portion of the CA1 region of the hippocampus and the prefrontal cortex as candidate regions for neuromodulation in schizophrenia. Medical Hypotheses, Vol. 80, Issue. 6, p. 827.


    Johansson, Anne-Sofie Owe-Larsson, Björn Asp, Linnéa Kocki, Tomasz Adler, Mats Hetta, Jerker Gardner, Renee Lundkvist, Gabriella B.S. Urbanska, Ewa M. and Karlsson, Håkan 2013. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: Cytokine challenge increases production of 3-hydroxykynurenine. Journal of Psychiatric Research, Vol. 47, Issue. 11, p. 1815.


    Lau, Benson WuiMan Lee, Jada ChiaDi and So, KwokFai 2013. Neurogenic hypothesis and psychiatric disorders. Chinese Science Bulletin, Vol. 58, Issue. 26, p. 3188.


    Bringas, Maria Elena Morales-Medina, Julio César Flores-Vivaldo, Yaredi Negrete-Diaz, Jose Vicente Aguilar-Alonso, Patricia León-Chávez, Bertha Alicia Lazcano-Ortiz, Zayda Monroy, Elibeth Rodríguez-Moreno, Antonio Quirion, Rémi and Flores, Gonzalo 2012. Clozapine administration reverses behavioral, neuronal, and nitric oxide disturbances in the neonatal ventral hippocampus rat. Neuropharmacology, Vol. 62, Issue. 4, p. 1848.


    Chen, Qian Kogan, Jeffrey H. Gross, Adam K. Zhou, Yuan Walton, Noah M. Shin, Rick Heusner, Carrie L. Miyake, Shinichi Tajinda, Katsunori Tamura, Kouichi and Matsumoto, Mitsuyuki 2012. SREB2/GPR85, a schizophrenia risk factor, negatively regulates hippocampal adult neurogenesis and neurogenesis-dependent learning and memory. European Journal of Neuroscience, Vol. 36, Issue. 5, p. 2597.


    Gilman, Sarah R Chang, Jonathan Xu, Bin Bawa, Tejdeep S Gogos, Joseph A Karayiorgou, Maria and Vitkup, Dennis 2012. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nature Neuroscience, Vol. 15, Issue. 12, p. 1723.


    Van Den Bossche, Maarten J.A. Van Wallendael, Kevin L.P. Strazisar, Mojca Sabbe, Bernard and Del-Favero, Jurgen 2012. Co-occurrence of Marfan syndrome and schizophrenia: What can be learned?. European Journal of Medical Genetics, Vol. 55, Issue. 4, p. 252.


    ×
  • Expert Reviews in Molecular Medicine, Volume 13
  • 2011, e25

Progress in defining the biological causes of schizophrenia

  • Benjamin Pickard (a1)
  • DOI: http://dx.doi.org/10.1017/S1462399411001955
  • Published online: 28 July 2011
Abstract

Schizophrenia is a common mental illness resulting from a complex interplay of genetic and environmental risk factors. Establishing its primary molecular and cellular aetiopathologies has proved difficult. However, this is a vital step towards the rational development of useful disease biomarkers and new therapeutic strategies. The advent and large-scale application of genomic, transcriptomic, proteomic and metabolomic technologies are generating data sets required to achieve this goal. This discovery phase, typified by its objective and hypothesis-free approach, is described in the first part of the review. The accumulating biological information, when viewed as a whole, reveals a number of biological process and subcellular locations that contribute to schizophrenia causation. The data also show that each technique targets different aspects of central nervous system function in the disease state. In the second part of the review, key schizophrenia candidate genes are discussed more fully. Two higher-order processes – adult neurogenesis and inflammation – that appear to have pathological relevance are also described in detail. Finally, three areas where progress would have a large impact on schizophrenia biology are discussed: deducing the causes of schizophrenia in the individual, explaining the phenomenon of cross-disorder risk factors, and distinguishing causative disease factors from those that are reactive or compensatory.

Copyright
Corresponding author
*Corresponding author: Benjamin Pickard, Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK. E-mail: benjamin.pickard@strath.ac.uk
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1P.F. Liddle (1987) The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. British Journal of Psychiatry 151, 145-151

2C.S. Karam (2010) Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences 31, 381-390

3A. Meyer-Lindenberg (2010) From maps to mechanisms through neuroimaging of schizophrenia. Nature 468, 194-202

4D. Segal (2007) Oligodendrocyte pathophysiology: a new view of schizophrenia. International Journal of Neuropsychopharmacology 10, 503-511

5S.E. Arnold (1999) Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Development and Psychopathology 11, 439-456

6S.S. Kety (1988) Schizophrenic illness in the families of schizophrenic adoptees: findings from the Danish national sample. Schizophrenia Bulletin 14, 217-222

8N. Risch (1990) Genetic linkage and complex diseases, with special reference to psychiatric disorders. Genetic Epidemiology 7, 3-16; discussion 17–45

10W. Bodmer and C. Bonilla (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nature Genetics 40, 695-701

11P. Lichtenstein (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373, 234-239

12H.J. Williams (2011) Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Human Molecular Genetics 20, 387-391

13N. Craddock and M.J. Owen (2005) The beginning of the end for the Kraepelinian dichotomy. British Journal of Psychiatry 186, 364-366

14J. Huang (2010) Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. American Journal of Psychiatry 167, 1254-1263

16P.J. Harrison and D.R. Weinberger (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 10, 40-68; image 45

17C.A. Ross (2006) Neurobiology of schizophrenia. Neuron 52, 139-153

18C.J. Carter (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophrenia Research 86, 1-14

19L.F. Jarskog , S. Miyamoto and J.A. Lieberman (2007) Schizophrenia: new pathological insights and therapies. Annual Review of Medicine 58, 49-61

20A. Hayashi-Takagi and A. Sawa (2010) Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Research Bulletin 83, 140-146

21N.J. Bray (2010) The neurobiology of schizophrenia: new leads and avenues for treatment. Current Opinion in Neurobiology 20, 810-815

22G. Kirov (2009) A genome-wide association study in 574 schizophrenia trios using DNA pooling. Molecular Psychiatry 14, 796-803

23M.C. O'Donovan (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics 40, 1053-1055

24T. Lencz (2007) Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Molecular Psychiatry 12, 572-580

29L. Athanasiu (2010) Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. Journal of Psychiatric Research 44, 748-753

31Z. Wang (2006) A review and re-evaluation of an association between the NOTCH4 locus and schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B, 902-906

33K. Wang , M. Li and H. Hakonarson (2010) Analysing biological pathways in genome-wide association studies. Nature Reviews. Genetics 11, 843-854

34P. Jia (2010) Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophrenia Research 122, 38-42

35C. O'Dushlaine (2011) Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Molecular Psychiatry 16, 286-292

36R. Redon (2006) Global variation in copy number in the human genome. Nature 444, 444-454

38D.F. Conrad (2010) Origins and functional impact of copy number variation in the human genome. Nature 464, 704-712

39D. Grozeva Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. Archives of General Psychiatry 67, 318-327

40G.W. Tam (2009) The role of DNA copy number variation in schizophrenia. Biological Psychiatry 66, 1005-1012

41A.S. Bassett , S.W. Scherer and L.M. Brzustowicz (2010) Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. American Journal of Psychiatry 167, 899-914

42J. Sebat , D.L. Levy and S.E. McCarthy (2009) Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends in Genetics 25, 528-535

43L.A. Weiss (2008) Association between microdeletion and microduplication at 16p11.2 and autism. New England Journal of Medicine 358, 667-675

44D. Moreno-De-Luca (2010) Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. American Journal of Human Genetics 87, 618-630

45C. Magri (2010) New copy number variations in schizophrenia. PLoS One 5, e13422

46J.G. Mulle Microdeletions of 3q29 confer high risk for schizophrenia. American Journal of Human Genetics 87, 229-236

47M. Karayiorgou , T.J. Simon and J.A. Gogos (2010) 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nature Reviews. Neuroscience 11, 402-416

48A. Ingason (2010) Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Molecular Psychiatry 16, 17-25

49International Schizophrenia Consortium (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455, 237-241

50H. Stefansson (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455, 232-236

51T. Walsh (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539-543

52S.E. McCarthy (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics 41, 1223-1227

53D.F. Levinson (2011) Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. American Journal of Psychiatry

54V. Vacic (2011) Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature

55S. Girirajan (2010) A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nature Genetics 42, 203-209

56G.A. Doody (1998) ‘Pfropfschizophrenie’ revisited. Schizophrenia in people with mild learning disability. British Journal of Psychiatry 173, 145-153

57D. Zhang (2009) Singleton deletions throughout the genome increase risk of bipolar disorder. Molecular Psychiatry 14, 376-380

59W.J. Muir , B.S. Pickard and D.H. Blackwood (2006) Chromosomal abnormalities and psychosis. British Journal of Psychiatry 188, 501-503

60J.E. Chubb (2008) The DISC locus in psychiatric illness. Molecular Psychiatry 13, 36-64

61J.K. Millar (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics 9, 1415-1423

62W.J. Muir , B.S. Pickard and D.H. Blackwood (2008) Disrupted-in-schizophrenia-1. Current Psychiatry Reports 10, 140-147

63D. St Clair (1990) Association within a family of a balanced autosomal translocation with major mental illness. Lancet 336, 13-16

64M.C. Gornick (2005) Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). Journal of Autism and Developmental Disorders 35, 831-838

65D.H. Blackwood (2001) Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. American Journal of Human Genetics 69, 428-433

66J.K. Millar (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310, 1187-1191

67Y. Ozeki (2011) A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. Neuroscience Research 69, 154-160

68B.S. Pickard (2008) A common variant in the 3′UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proceedings of the National Academy of Sciences of the United States of America 105, 14940-14945

69B.S. Pickard (2006) Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Molecular Psychiatry 11, 847-857

70H.C. Whalley (2009) A GRIK4 variant conferring protection against bipolar disorder modulates hippocampal function. Molecular Psychiatry 14, 467-468

71H.M. Knight (2009) A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. American Journal of Human Genetics 85, 833-846

72D. Kamnasaran (2003) Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. Journal of Medical Genetics 40, 325-332

73B.S. Pickard (2009) Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Molecular Psychiatry 14, 874-884

74B.S. Pickard (2005) Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 136B, 26-32

75M.A. Ferreira (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nature Genetics 40, 1056-1058

76Y. Li (2010) Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nature Genetics 42, 969-972

77K. Bilguvar (2010) Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. Nature 467, 207-210

78W. Song (2008) Identification of high risk DISC1 structural variants with a 2% attributable risk for schizophrenia. Biochemical and Biophysical Research Communications 367, 700-706

79J. Tarabeux (2010) De novo truncating mutation in Kinesin 17 associated with schizophrenia. Biological Psychiatry 68, 649-656

80S.R. Datta (2010) A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia. Molecular Psychiatry 15, 615-628

81S. Dwyer (2011) Investigation of rare non-synonymous variants at ABCA13 in schizophrenia and bipolar disorder. Molecular Psychiatry, 2011 February 1 [Epub ahead of print]

82R.H. Porter , S.L. Eastwood and P.J. Harrison (1997) Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Research 751, 217-231

83B.P. Sokolov (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of “neuroleptic-free” schizophrenics: evidence on reversible up-regulation by typical neuroleptics. Journal of Neurochemistry 71, 2454-2464

84J.H. Meador-Woodruff , K.L. Davis and V. Haroutunian (2001) Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 24, 545-552

85I. Singh and N. Rose (2009) Biomarkers in psychiatry. Nature 460, 202-207

87C.A. Altar , M.P. Vawter and S.D. Ginsberg (2009) Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34, 18-54

89S. Horvath , Z. Janka and K. Mirnics (2011) Analyzing schizophrenia by DNA microarrays. Biological Psychiatry 69, 157-162

90D.A. Lewis and K. Mirnics (2006) Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. Progress in Brain Research 158, 141-152

91K. Mirnics , P. Levitt and D.A. Lewis (2006) Critical appraisal of DNA microarrays in psychiatric genomics. Biological Psychiatry 60, 163-176

92K. Iwamoto and T. Kato (2006) Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 12, 349-361

93D. Arion (2007) Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biological Psychiatry 62, 711-721

94T. Hashimoto (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 13, 147-161

95N.A. Matigian (2008) Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative? PLoS One 3, e2412

96P.F. Sullivan , C. Fan and C.M. Perou (2006) Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B, 261-268

97M. Takahashi (2010) Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophrenia Research 119, 210-218

98F.A. Middleton (2005) Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 136B, 12-25

99C.E. Duncan , A.F. Chetcuti and P.R. Schofield (2008) Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatric Genetics 18, 226-239

100S. Sivagnanasundaram (2007) Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia. Brain Research 1139, 48-59

101M.H. Polymeropoulos (2009) Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophrenia Research 108, 134-142

102B. Xu , M. Karayiorgou and J.A. Gogos (2010) MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Research 1338, 78-88

103D.A. Forero (2010) miRNA genes and the brain: implications for psychiatric disorders. Human Mutation 31, 1195-1204

104E. Schwarz and S. Bahn (2008) Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Review of Molecular Diagnostics 8, 209-216

105J.A. English (2011) The neuroproteomics of schizophrenia. Biological Psychiatry 69, 163-172

106Y. Levin (2010) Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Molecular Psychiatry 15, 1088-1100

107D. Martins-de-Souza (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. Journal of Psychiatric Research 44, 1176-1189

108D. Martins-de-Souza (2009) Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 9, 17

109N.L. Johnston-Wilson (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Molecular Psychiatry 5, 142-149

110J.A. English (2009) 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9, 3368-3382

112J.T. Huang (2007) CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2, e756

113J.T. Huang (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3, e428

115S. Thakker-Varia (2007) The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. Journal of Neuroscience 27, 12156-12167

116J.G. Hunsberger (2007) Antidepressant actions of the exercise-regulated gene VGF. Nature Medicine 13, 1476-1482

117A. Bartolomucci (2007) The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes and Nutrition 2, 169-180

119J.K. Nicholson and J.C. Lindon (2008) Systems biology: metabonomics. Nature 455, 1054-1056

120M.P. Quinones and R. Kaddurah-Daouk (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiology of Disease 35, 165-176

121R. Kaddurah-Daouk and K.R. Krishnan (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186

122R. Kaddurah-Daouk (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry 12, 934-945

123A. Kale (2008) Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophrenia Research 98, 295-301

124B.M. Ross (2003) Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins, Leukotrienes, and Essential Fatty Acids 69, 407-412

125G.E. Berger , S. Smesny and G.P. Amminger (2006) Bioactive lipids in schizophrenia. International Review of Psychiatry 18, 85-98

126K.Q. Do (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Current Opinion in Neurobiology 19, 220-230

127J.K. Yao and M.S. Keshavan (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxidants and Redox Signaling, 2011 May 4 [Epub ahead of print]

128J.F. Wang (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disorder 11, 523-529

129K.Q. Do (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 12, 3721-3728

130J.K. Yao , S. Leonard and R. Reddy (2006) Altered glutathione redox state in schizophrenia. Disease Markers 22, 83-93

131B. Rodriguez-Santiago (2010) Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. Molecular Psychiatry 15, 1023-1033

132E. Holmes (2006) Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Medicine 3, e327

133H.B. Clay , S. Sillivan and C. Konradi (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. International Journal of Developmental Neuroscience

134F. Scaglia (2010) The role of mitochondrial dysfunction in psychiatric disease. Developmental Disabilities Research Reviews 16, 136-143

135L. Dixon (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26, 903-912

137B. Rollins (2009) Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One 4, e4913

138J.K. Millar (2005) Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. Molecular and Cellular Neurosciences 30, 477-484

139R. James (2004) Disrupted in schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Molecular and Cellular Neurosciences 26, 112-122

140Y.U. Park (2010) Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. Proceedings of the National Academy of Sciences of the United States of America 107, 17785-17790

141R.E. Straub (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics 71, 337-348

142H. Stefansson (2002) Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 71, 877-892

143A.Y. Guo (2009) The dystrobrevin-binding protein 1 gene: features and networks. Molecular Psychiatry 14, 18-29

144A. Buonanno (2010) The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Research Bulletin 83, 122-131

145A. Banerjee (2010) Neuregulin 1-erbB4 pathway in schizophrenia: from genes to an interactome. Brain Research Bulletin 83, 132-139

146N.J. Brandon (2009) Understanding the role of DISC1 in psychiatric disease and during normal development. Journal of Neuroscience 29, 12768-12775

147L.M. Camargo (2007) Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Molecular Psychiatry 12, 74-86

148T. Hattori (2007) A novel DISC1-interacting partner DISC1-binding zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Molecular Psychiatry 12, 398-407

149J.K. Millar , S. Christie and D.J. Porteous (2003) Yeast two-hybrid screens implicate DISC1 in brain development and function. Biochemical and Biophysical Research Communications 311, 1019-1025

150K. Miyoshi (2004) DISC1 localizes to the centrosome by binding to kendrin. Biochemical and Biophysical Research Communications 317, 1195-1199

151K. Miyoshi (2003) Disrupted-in-schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Molecular Psychiatry 8, 685-694

152J.A. Morris (2003) DISC1 (Disrupted-in-schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Human Molecular Genetics 12, 1591-1608

153F. Ogawa , M. Kasai and T. Akiyama (2005) A functional link between disrupted-in-schizophrenia 1 and the eukaryotic translation initiation factor 3. Biochemical and Biophysical Research Communications 338, 771-776

154Y. Ozeki (2003) Disrupted-in-schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proceedings of the National Academy of Sciences of the United States of America 100, 289-294

155A. Hayashi-Takagi (2010) Disrupted-in-schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nature Neuroscience 13, 327-332

156Y. Hirohashi (2006) Centrosomal proteins Nde1 and Su48 form a complex regulated by phosphorylation. Oncogene 25, 6048-6055

157Q. Wang (2006) Characterization of Su48, a centrosome protein essential for cell division. Proceedings of the National Academy of Sciences of the United States of America 103, 6512-6517

158A. Kamiya (2008) Recruitment of PCM1 to the centrosome by the cooperative action of DISC1 and BBS4: a candidate for psychiatric illnesses. Archives of General Psychiatry 65, 996-1006

159T. Fukuda (2010) CAMDI, a novel disrupted in schizophrenia 1 (DISC1)-binding protein, is required for radial migration. Journal of Biological Chemistry 285, 40554-40561

160A. Enomoto (2009) Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron 63, 774-787

161J.Y. Kim (2009) DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 63, 761-773

162N.J. Bradshaw (2008) DISC1, PDE4B, and NDE1 at the centrosome and synapse. Biochemical and Biophysical Research Communications 377, 1091-1096

163N.J. Brandon (2004) Disrupted in schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Molecular and Cellular Neurosciences 25, 42-55

164S. Taya (2007) DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. Journal of Neuroscience 27, 15-26

165K.K. Singh (2010) Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron 67, 33-48

166R. Toro (2010) Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends in Genetics 26, 363-372

167L.N. van de Lagemaat and S.G. Grant (2010) Genome variation and complexity in the autism spectrum. Neuron 67, 8-10

168L. Krabbendam and J. van Os (2005) Schizophrenia and urbanicity: a major environmental influence–conditional on genetic risk. Schizophrenia Bulletin 31, 795-799

169A.N. van den Pol (2009) Viral infection leading to brain dysfunction: more prevalent than appreciated? Neuron 64, 17-20

170R.H. Yolken , F.B. Dickerson and E. Fuller Torrey (2009) Toxoplasma and schizophrenia. Parasite Immunology 31, 706-715

171S.A. Henriquez (2009) Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation 16, 122-133

172Y. Watanabe , T. Someya and H. Nawa (2010) Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry and Clinical Neurosciences 64, 217-230

173W. Laan (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 71, 520-527

174S.E. Baranzini (2009) The genetics of autoimmune diseases: a networked perspective. Current Opinion in Immunology 21, 596-605

175B. Abazyan (2010) Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biological Psychiatry 68, 1172-1181

177D. Ibi (2010) Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behavioural Brain Research 206, 32-37

178J.C. Barrett (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics 40, 955-962

179C. Turnbull (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genetics 42, 504-507

180L.M. Boulanger (2009) Immune proteins in brain development and synaptic plasticity. Neuron 64, 93-109

181N. Kolluri (2005) Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. American Journal of Psychiatry 162, 1200-1202

182R.A. Sweet (2009) Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 34, 374-389

183L.A. Glantz and D.A. Lewis (2001) Dendritic spine density in schizophrenia and depression. Archives of General Psychiatry 58, 203

184G. Kempermann , J. Krebs and K. Fabel (2008) The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Current Opinion in Psychiatry 21, 290-295

185C.T. Toro and J.F. Deakin (2007) Adult neurogenesis and schizophrenia: a window on abnormal early brain development? Schizophrenia Research 90, 1-14

186A. Reif (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Molecular Psychiatry

187W. Deng , J.B. Aimone and F.H. Gage (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nature Reviews. Neuroscience 11, 339-350

188M.W. Marlatt and P.J. Lucassen (2010) Neurogenesis and Alzheimer's disease: biology and pathophysiology in mice and men. Current Alzheimer Research 7, 113-125

189R. Vandenbosch (2009) Adult neurogenesis and the diseased brain. Current Medicinal Chemistry 16, 652-666

190N. Kaneko and K. Sawamoto (2009) Adult neurogenesis and its alteration under pathological conditions. Neuroscience Research 63, 155-164

191K.A. Sailor , G.L. Ming and H. Song (2006) Neurogenesis as a potential therapeutic strategy for neurodegenerative diseases. Expert Opinion on Biological Therapy 6, 879-890

192B. Steiner , S. Wolf and G. Kempermann (2006) Adult neurogenesis and neurodegenerative disease. Regenerative Medicine 1, 15-28

193T. Hikida (2007) Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proceedings of the National Academy of Sciences of the United States of America 104, 14501-14506

194M. Kvajo (2008) A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proceedings of the National Academy of Sciences of the United States of America 105, 7076-7081

195M.V. Pletnikov (2008) Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Molecular Psychiatry 13, 173-186, 115

196M.V. Pletnikov (2008) Enlargement of the lateral ventricles in mutant DISC1 transgenic mice. Molecular Psychiatry 13, 115

197S. Shen (2008) Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. Journal of Neuroscience 28, 10893-10904

198N.M. Fournier , H.J. Caruncho and L.E. Kalynchuk (2009) Decreased levels of disrupted-in-schizophrenia 1 (DISC1) are associated with expansion of the dentate granule cell layer in normal and kindled rats. Neuroscience Letters 455, 134-139

199K.D. Meyer and J.A. Morris (2009) Disc1 regulates granule cell migration in the developing hippocampus. Human Molecular Genetics

200G.L. Ming and H. Song (2009) DISC1 partners with GSK3beta in neurogenesis. Cell 136, 990-992

201X. Duan (2007) Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 130, 1146-1158

202A.A. Pieper (2005) The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proceedings of the National Academy of Sciences of the United States of America 102, 14052-14057

203E.W. Brunskill (2005) Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. European Journal of Neuroscience 22, 1265-1276

204C. Erbel-Sieler (2004) Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proceedings of the National Academy of Sciences of the United States of America 101, 13648-13653

205A.A. Pieper (2010) Discovery of a proneurogenic, neuroprotective chemical. Cell 142, 39-51

206A.C. Nica (2010) Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genetics 6, e1000895

207A.C. Nica and E.T. Dermitzakis (2008) Using gene expression to investigate the genetic basis of complex disorders. Human Molecular Genetics 17, R129-R134

208D.H. Geschwind and G. Konopka (2009) Neuroscience in the era of functional genomics and systems biology. Nature 461, 908-915

209J.B. Veyrieras (2008) High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genetics 4, e1000214

210Y. Gilad , S.A. Rifkin and J.K. Pritchard (2008) Revealing the architecture of gene regulation: the promise of eQTL studies. Trends in Genetics 24, 408-415

211W. Hennah and D. Porteous (2009) The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes. PLoS One 4, e4906

213S.J. Chamberlain , X.J. Li and M. Lalande (2008) Induced pluripotent stem (iPS) cells as in vitro models of human neurogenetic disorders. Neurogenetics 9, 227-235

214K.J. Brennand (2011) Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225

215C.H. Chiang (2011) Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Molecular Psychiatry 16, 358-360

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×